Breast Cancer Update Home - Oncology Leader Commentary

Home: Oncology Leader Commentary: Gershon Locker, MD

Click on the topic below for comments by Dr Gershon Locker to comment on. You will also find links to related articles and clinical trials.

Trials of first line Arimidex
Choosing first-line endocrine therapy in postmenopausal patients
Vasomotor symptoms and Arimidex
Mechanisms of resistance to endocrine therapy
Tamoxifen rechallenge versus Arimidex
Aromatase inhibitors when adjuvant tamoxifen is contraindicated
ATAC adjuvant trial: Arimidex vs Tamoxifen vs the Combination

Home

Patrick I. Borgen, MD

Aman Buzdar, MD

Nancy E. Davidson, MD

J. Michael Dixon, MD

Armando Giuliano, MD

I. Craig Henderson, MD

David Krag, MD

Gershon Locker, MD

Charles Loprinzi, MD

Richard Margolese, MD

Monica Morrow, MD

C Kent Osborne, MD

Sir Richard Peto, FRS

Kathy I. Pritchard, MD

John F. Robertson, MD,FRCS

Andrew D. Seidman, MD

George W. Sledge, MD

Home · Contact us

Terms of use and general disclaimer